非盲随机放疗技术试验中患者认知:治疗误解的调查研究
本研究在左侧淋巴结阳性乳腺癌患者中,评估其参与IMRT-DIBH对比3DCRT随机试验时的治疗误解倾向。研究提示需通过知情同意调整期望以减少治疗误解。
要点
- 多数患者认为试验参与可获更好治疗和更多医疗关注。
- 基线时74%认为新技术优于 established 技术。
- 44%的3DCRT组患者希望被分配至IMRT-DIBH组。
核心结论
- 多数参与者报告试验参与会带来更好治疗和更多医疗关注,这是治疗误解的特征。
- 观察结果提供了患者固定相信新技术优越性的经验证据,强调通过知情同意调整期望以减少治疗误解的重要性。
研究设计与样本
- 在左侧淋巴结阳性乳腺癌患者中开展的随机临床试验配套调查研究,比较IMRT-DIBH与3DCRT。
主要发现
- 77%的参与者认为试验参与可能带来比当前标准治疗更好的治疗,54%认为可获得更多医疗关注。
- 基线时74%的女性认为新技术优于 established 技术。
- 随机前,43%认为IMRT-DIBH比3DCRT标准治疗更有效,无人认为3DCRT更有效,23%认为两者相同,34%不知道。
- 无人认为IMRT-DIBH会导致更差的长期副作用,而37%认为3DCRT会。
- 71%报告会选择IMRT-DIBH治疗,若可选择无人会选择3DCRT;3DCRT组44%希望被分配至IMRT-DIBH组,IMRT-DIBH组无人希望交叉。
临床怎么用
- 知情同意过程中应明确说明试验的科学目的,调整患者对新技术优越性的期望,以减少治疗误解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Therapeutic misconception is the tendency for a clinical trial participant to overlook the scientific objective of a clinical trial and instead believe that an experimental intervention is intended for personal therapeutic benefit. We sought to evaluate this tendency in the setting of a clinical trial of a new radiation therapy technology. METHODS: Patients with left-sided, node positive breast cancer enrolled in a randomized clinical trial evaluating intensity modulated radiation therapy with deep inspiration breath hold (IMRT-DIBH) versus 3-dimensional conformal radiation therapy (3DCRT). Patients who enrolled completed surveys at baseline, after randomization, and upon completion of radiation therapy to evaluate expectations, satisfaction, and experiences. RESULTS: Forty women participated in the survey study, with 20 in each arm. Most participants endorsed the perception that participation in the trial might result in better treatment than the current standard treatment (77%) and more medical attention than being off trial (54%). At baseline, most women (74%) believed that a new treatment technology is superior than an established one. Before randomization, 43% of participants believed IMRT-DIBH would be more effective than standard treatment with 3DCRT, none believed that 3DCRT would be more effective, 23% believed that they would be the same, and 34% did not know. None believed that IMRT-DIBH would cause worse long-term side effects, whereas 37% thought that 3DCRT would. Most (71%) reported that they would choose to be treated with IMRT-DIBH; none would have elected 3DCRT if given a choice. Nearly half (44%) in the 3DCRT arm wished that they had been assigned to the IMRT-DIBH arm; none in the IMRT-DIBH arm expressed a wish for crossover. CONCLUSIONS: Most participants reported the perception that trial participation would result in better treatment and more medical attention than off trial, hallmarks of therapeutic misconception. Our observations provide empirical evidence of a fixed belief in the superiority of new technology and highlight the importance of adjusting expectations through informed consent to mitigate therapeutic misconception.
引用
- Shumway DA, Motomura A, Griffith KA, et al. Patient Perceptions in a Nonblinded Randomized Trial of Radiation Therapy Technologies: A Novel Survey Study Exploring Therapeutic Misconception. Int J Radiat Oncol Biol Phys. 2020. PMID: 32454191. doi:10.1016/j.ijrobp.2020.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。